000169758 001__ 169758
000169758 005__ 20240229133654.0
000169758 0247_ $$2doi$$a10.1093/neuonc/noab158
000169758 0247_ $$2pmid$$apmid:34232320
000169758 0247_ $$2ISSN$$a1522-8517
000169758 0247_ $$2ISSN$$a1523-5866
000169758 0247_ $$2altmetric$$aaltmetric:108889280
000169758 037__ $$aDKFZ-2021-01541
000169758 041__ $$aEnglish
000169758 082__ $$a610
000169758 1001_ $$0P:(DE-He78)98da1f9d3c5ced2d8867edfe9f681ddc$$aAlhalabi, Obada$$b0$$eFirst author$$udkfz
000169758 245__ $$aA novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.
000169758 260__ $$aOxford$$bOxford Univ. Press$$c2022
000169758 3367_ $$2DRIVER$$aarticle
000169758 3367_ $$2DataCite$$aOutput Types/Journal article
000169758 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642165167_14743
000169758 3367_ $$2BibTeX$$aARTICLE
000169758 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169758 3367_ $$00$$2EndNote$$aJournal Article
000169758 500__ $$aB067#LA:B067# / 2022 Jan 5;24(1):39-51 / Junior Research Group Bioinformatics and Omics Data Analytics
000169758 520__ $$aGlioblastoma is the most common primary malignancy of the central nervous system with dismal prognosis. Genomic signatures classify isocitrate dehydrogenase 1 (IDH)-wildtype glioblastoma into three subtypes: proneural, mesenchymal and classical. Dasatinib, an inhibitor of proto-oncogene kinase Src (SRC), is one of many therapeutics which, despite promising preclinical results, has failed to improve overall survival in glioblastoma patients in clinical trials. We examined whether glioblastoma subtypes differ in their response to dasatinib and could hence be evaluated for patient enrichment strategies in clinical trials.We carried out in silico analyses on glioblastoma gene expression (TCGA) and single-cell RNA-Seq data. In addition, in vitro experiments using glioblastoma stem-like cells (GSCs) derived from primary patient tumors were performed, with complementary gene expression profiling and immunohistochemistry analysis of tumor samples.Patients with the mesenchymal subtype of glioblastoma showed higher SRC pathway activation based on gene expression profiling. Accordingly, mesenchymal GSCs were more sensitive to SRC inhibition by dasatinib compared to proneural and classical GSCs. Notably, SRC phosphorylation status did not predict response to dasatinib treatment. Furthermore, serpin peptidase inhibitor clade H member 1 (SERPINH1), a collagen related heat-shock protein associated with cancer progression, was shown to correlate with dasatinib response and with the mesenchymal subtype.This work highlights further molecular-based patient selection strategies in clinical trials and suggests the mesenchymal subtype as well as SERPINH1 to be associated with response to dasatinib. Our findings indicate that stratification based on gene expression subtyping should be considered in future dasatinib trials.
000169758 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000169758 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169758 650_7 $$2Other$$aDasatinib
000169758 650_7 $$2Other$$aGlioblastoma
000169758 650_7 $$2Other$$aGlioblastoma stem-like cells
000169758 650_7 $$2Other$$aSERPINH1
000169758 650_7 $$2Other$$aSRC
000169758 7001_ $$0P:(DE-He78)531cf6e04ba45b3c088cd4d4d3cc3c36$$aFletcher, Michael N C$$b1$$udkfz
000169758 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b2$$udkfz
000169758 7001_ $$0P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aKessler, Tobias$$b3$$udkfz
000169758 7001_ $$0P:(DE-He78)3bdc7fb5a6314e2f3be584df6007b4ae$$aLokumcu, Tolga$$b4$$udkfz
000169758 7001_ $$aBaumgartner, Ulrich$$b5
000169758 7001_ $$0P:(DE-He78)a1c091dac6ebb89655fc4875ff069c3c$$aWittmann, Elena$$b6
000169758 7001_ $$0P:(DE-He78)880900065fdfb634b00cd591b801ee42$$aSchlue, Silja$$b7$$udkfz
000169758 7001_ $$0P:(DE-He78)442ee8f54d846d943023a916889feb8e$$aGöttmann, Mona$$b8$$udkfz
000169758 7001_ $$0P:(DE-He78)e1ec266c8157128d4596c3b2f520e30d$$aRahman, Shaman$$b9
000169758 7001_ $$0P:(DE-He78)7cde365fa8f836be201c050de81e7a03$$aHai, Ling$$b10$$udkfz
000169758 7001_ $$0P:(DE-HGF)0$$aHansen-Palmus, Lea$$b11
000169758 7001_ $$0P:(DE-He78)39a8becd6fa9602e4871d18f3f6f8e09$$aPuccio, Laura$$b12$$udkfz
000169758 7001_ $$aNakano, Ichiro$$b13
000169758 7001_ $$aHerold-Mende, Christel$$b14
000169758 7001_ $$aDay, Bryan W$$b15
000169758 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b16$$udkfz
000169758 7001_ $$aSahm, Felix$$b17
000169758 7001_ $$0P:(DE-He78)830be4979a39935ac6272eaebad5982a$$aPhillips, Emma$$b18$$udkfz
000169758 7001_ $$0P:(DE-HGF)0$$aGoidts, Violaine$$b19$$eLast author
000169758 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noab158$$gp. noab158$$n1$$p39-51 $$tNeuro-Oncology$$v24$$x1523-5866$$y2022
000169758 909CO $$ooai:inrepo02.dkfz.de:169758$$pVDB
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)98da1f9d3c5ced2d8867edfe9f681ddc$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)531cf6e04ba45b3c088cd4d4d3cc3c36$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3bdc7fb5a6314e2f3be584df6007b4ae$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1c091dac6ebb89655fc4875ff069c3c$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)880900065fdfb634b00cd591b801ee42$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)442ee8f54d846d943023a916889feb8e$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e1ec266c8157128d4596c3b2f520e30d$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7cde365fa8f836be201c050de81e7a03$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)39a8becd6fa9602e4871d18f3f6f8e09$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)830be4979a39935ac6272eaebad5982a$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000169758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000169758 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000169758 9130_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000169758 9141_ $$y2021
000169758 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000169758 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000169758 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-08$$wger
000169758 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000169758 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000169758 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000169758 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000169758 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2021$$d2022-11-08
000169758 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000169758 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bNEURO-ONCOLOGY : 2021$$d2022-11-08
000169758 9201_ $$0I:(DE-He78)B067-20160331$$kB067$$lB067 Translationale Zielmoleküle für Hirntumoren$$x0
000169758 9201_ $$0I:(DE-He78)B060-20160331$$kB060$$lB060 Molekulare Genetik$$x1
000169758 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x2
000169758 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x3
000169758 980__ $$ajournal
000169758 980__ $$aVDB
000169758 980__ $$aI:(DE-He78)B067-20160331
000169758 980__ $$aI:(DE-He78)B060-20160331
000169758 980__ $$aI:(DE-He78)C060-20160331
000169758 980__ $$aI:(DE-He78)B320-20160331
000169758 980__ $$aUNRESTRICTED